Gastric mucosal damage in XXXX --effects of pretreatment with a synthetic prostaglandin E1 analogue.

@entity295 @entity1819 @entity1066 @entity396 @entity5828 @entity468 @entity526 @entity2275
An experimental model was used which includes intragastric instillation of 80 mM @entity5828 and 0.6 ml bile/kg followed by intravenous infusion of live @entity526 in @entity468 for up to three hours. This procedure regularly induces @entity2275 . Mucosal blood flow was measured by microspheres before, early, and late in @entity295 . Total gastric blood flow was recorded electromagnetically. Mucosal regeneration capacity as reflected by the RNA/DNA ratio was measured. @entity396 (a PGE1 analogue) was infused iv (5 micrograms/kg X h) or given locally in the stomach (10 micrograms/kg) before bacteriemia. @entity396 did not influence the haemodynamic response to bacteria. The @entity1819 was assessed either as an index representative for the entire corpus-fundus region or as the number of areas with intact surface epithelium within the series. @entity396 iv protected the mucosa from @entity1066 compared with untreated septic controls while @entity396 intragastrically significantly reduced the number of damaged areas only. Topical @entity396 increased total @entity1819 flows early in @entity295 compared to iv or no pretreatment while no difference was seen during late @entity295 . The protective effect of @entity396 was thus not dependent on increased gastric mucosal blood flow. Nor was it mediated through effects on mucosal nucleic acid concentrations or ratio.
